Pedscases Viral Rashes Video
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Roseola Fact Sheet
Sixth Disease/ Exanthem Subitum DISTRICT OF COLUMBIA DEPARTMENT OF HEALTH Division of Epidemiology, Disease Surveillance and Investigation 899 N. Capitol Street, NE, Suite 580 Washington, D.C. 20002 202-442-9371 Fax 202-442-8060 * www.dchealth.dc.gov What is Roseola? medications. Frequent hand washing may Roseola is an acute, febrile rash illness caused by a limit transmission (spread). Women who are virus. pregnant and have been exposed to this illness should discuss the exposure with Who gets Fifth Disease? their doctor. Roseola occurs in children usually under four years of age. It is most common in children under the age Should a child with Roseola be excluded of two. from Child-care? Yes, a child with fever and rash should be What are the symptoms of Roseola? excluded from child-care until seen by a The symptoms of roseola include a high fever that health-care provider. The child may return lasts for three to five days. A runny nose, irritability, to child-care once the fever has gone, even if eyelid swelling, and tiredness may also be present. the rash is present. When the fever disappears, a rash appears, mainly on the face and body. How can Roseola be prevented? There is no vaccine or medicine that How is Roseola spread? prevents roseola. Frequent and thorough Roseola is spread from person to person but the hand washing is recommended as a practical exact way is not known. It appears that saliva may be and effective method of preventing most an important way for the spread of the virus. -
Communicable Disease Chart
COMMON INFECTIOUS ILLNESSES From birth to age 18 Disease, illness or organism Incubation period How is it spread? When is a child most contagious? When can a child return to the Report to county How to prevent spreading infection (management of conditions)*** (How long after childcare center or school? health department* contact does illness develop?) To prevent the spread of organisms associated with common infections, practice frequent hand hygiene, cover mouth and nose when coughing and sneezing, and stay up to date with immunizations. Bronchiolitis, bronchitis, Variable Contact with droplets from nose, eyes or Variable, often from the day before No restriction unless child has fever, NO common cold, croup, mouth of infected person; some viruses can symptoms begin to 5 days after onset or is too uncomfortable, fatigued ear infection, pneumonia, live on surfaces (toys, tissues, doorknobs) or ill to participate in activities sinus infection and most for several hours (center unable to accommodate sore throats (respiratory diseases child’s increased need for comfort caused by many different viruses and rest) and occasionally bacteria) Cold sore 2 days to 2 weeks Direct contact with infected lesions or oral While lesions are present When active lesions are no longer NO Avoid kissing and sharing drinks or utensils. (Herpes simplex virus) secretions (drooling, kissing, thumb sucking) present in children who do not have control of oral secretions (drooling); no exclusions for other children Conjunctivitis Variable, usually 24 to Highly contagious; -
Juvenile Recurrent Parotitis and Sialolithiasis: an Noteworthy Co-Existence
Otolaryngology Open Access Journal ISSN: 2476-2490 Juvenile Recurrent Parotitis and Sialolithiasis: An Noteworthy Co-Existence Venkata NR* and Sanjay H Case Report Department of ENT and Head & Neck Surgery, Kohinoor Hospital, India Volume 3 Issue 1 Received Date: April 20, 2018 *Corresponding author: Nataraj Rajanala Venkata, Department of ENT and Head & Published Date: May 21, 2018 Neck Surgery, Kohinoor Hospital, Kurla (W), Mumbai, India, Tel: +918691085580; DOI: 10.23880/ooaj-16000168 Email: [email protected] Abstract Juvenile Recurrent Parotitis is a relatively rare condition. Sialolithiasis co-existing along with Juvenile Recurrent Parotitis is an even rarer occurrence. We present a case of Juvenile Recurrent Parotitis and Sialolithiasis in a 6 years old male child and how we managed it. Keywords: Juvenile Recurrent Parotitis; Parotid gland; Swelling; Sialolithiasis Introduction child. Tuberculosis was suspected but the tests yielded no results. Even MRI of the parotid gland failed to reveal any Juvenile Recurrent Parotitis is characterized by cause. Then the patient was referred to us for definitive recurring episodes of swelling usually accompanied by management. Taking the history into consideration, a pain in the parotid gland. Associated symptoms usually probable diagnosis of Juvenile Recurrent Parotitis due to include fever and malaise. It is most commonly seen in sialectasis was considered. CT Sialography revealed children, but may persist into adulthood. Unlike parotitis, dilatation of the main duct and the ductules with which is caused by infection or obstructive causes like collection of the dye at the termination of the terminal calculi, fibromucinous plugs, duct stenosis and foreign ductules, in the left parotid gland. -
Evaluation of the Tetracore Orthopox Biothreat® Antigen Detection Assay
Journal of Virological Methods 187 (2013) 37–42 Contents lists available at SciVerse ScienceDirect Journal of Virological Methods jou rnal homepage: www.elsevier.com/locate/jviromet ® Evaluation of the Tetracore Orthopox BioThreat antigen detection assay using laboratory grown orthopoxviruses and rash illness clinical specimens a,∗ b a a a Michael B. Townsend , Adam MacNeil , Mary G. Reynolds , Christine M. Hughes , Victoria A. Olson , a a Inger K. Damon , Kevin L. Karem a Centers for Disease Control and Prevention, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, 1600 Clifton Road NE, Mailstop G-06, Atlanta, GA 30333, United States b Centers for Disease Control and Prevention, Global Immunization Division, CGH, 1600 Clifton Road NE, Mailstop G-06, Atlanta, GA 30333, United States a b s t r a c t ® Article history: The commercially available Orthopox BioThreat Alert assay for orthopoxvirus (OPV) detection is piloted. Received 5 December 2011 This antibody-based lateral-flow assay labels and captures OPV viral agents to detect their presence. Serial Received in revised form 23 August 2012 dilutions of cultured Vaccinia virus (VACV) and Monkeypox virus (MPXV) were used to evaluate the sensi- Accepted 30 August 2012 tivity of the Tetracore assay by visual and quantitative determinations; specificity was assessed using a Available online 5 September 2012 small but diverse set of diagnostically relevant blinded samples from viral lesions submitted for routine ® OPV diagnostic testing. The BioThreat Alert assay reproducibly detected samples at concentrations of Keywords: 7 6 10 pfu/ml for VACV and MPXV and positively identified samples containing 10 pfu/ml in 4 of 7 inde- Monkeypox Orthopoxvirus pendent experiments. -
Adult Vaccines
What do flu, whooping cough, measles, shingles and pneumonia have in common? 1 They’re viruses that can make you very sick. 2 Vaccines can help prevent them. Protect yourself and those you care about. Get vaccinated at a network pharmacy near you. • Ask your pharmacist which vaccines are right for you. • Find out if your pharmacist can administer the recommended vaccinations. • Many vaccinations are covered by your plan at participating retail pharmacies. • Don’t forget to present your member ID card to the pharmacist at the time of service! The following vaccines are available and can be administered by pharmacists at participating network pharmacies: • Flu (seasonal influenza) • Meningitis • Travel Vaccines (typhoid, yellow • Tetanus/Diphtheria/Pertussis • Pneumonia fever, etc.) • Hepatitis • Rabies • Childhood Vaccines (MMR, etc.) • Human Papillomavirus (HPV) • Shingles/Zoster See other side for recommended adult vaccinations. The vaccinations you need ALL adults should get vaccinated for1: • Flu, every year. It’s especially important for pregnant women, older adults and people with chronic health conditions. • Tetanus, diphtheria and pertussis (whooping cough). Adults should get a one-time dose of the Tdap vaccine. It’s different from the tetanus vaccine (Td), which is given every 10 years. You may need additional vaccinations depending on your age1: Young adults not yet vaccinated need: Human papillomavirus (HPV) vaccine series (3 doses) if you are: • Female age 26 or younger • Male age 21 or younger • Male age 26 or younger who has sex with men, who is immunocompromised or who has HIV Adults born in the U.S. in 1957 or after need: Measles, mumps, rubella (MMR) vaccine2 Adults should get at least one dose of MMR vaccine, unless they’ve already gotten this vaccine or have immunity to measles, mumps and rubella Adults born in the U.S. -
Seroprevalence of TORCH Infections in Children
Chattagram Maa-O-Shishu Hospital Medical College Journal Volume 17, Issue 1, January 2018 Original Article Seroprevalence of TORCH Infections in Children Sanjoy Kanti Biswas1* Abstract 2 Md. Badruddoza Background : The acronym “TORCH” was introduced to highlight a group of Nahid Sultana1 pathogens that cause a congenital and perinatal infections: Toxoplasma gondi, rubella virus, Cytomegalovirus (CMV) and Herpes Simplex Virus (HSV). These pathogens are often associated with congenital anomalies. Congenital malformations 1 Department of Microbiology have a direct impact on the family. This study was undertaken to detect the Chattagram Maa-O-Shishu Hospital Medical College Chittagong, Bangladesh. serological evidence of TORCH infections in children, by establishing the presence of specific IgM antibodies. Methods: During the period 1st June 2016 to 30th May 2 Department of Paediatrics 2017, 58 suspected TORCH infection cases were included from Paediatrics Chattagram Maa-O-Shishu Hospital Medical College Chittagong, Bangladesh. Department of CMOSH for TORCH antibody detection. The children were in the age of 0 day to 1 year with an average age of 3.3±2.59 months. The serum samples were tested forIgM and IgG antibodies against TORCH agents by using enzyme linked immunoassay method (ELISA). Results: Among the 58 children, seropositivity was found in 55 (94.82%) cases. Of the 55 seropositive cases serological evidence for combination of IgM and IgG with any one of the TORCH agents was detected in 25 (43.10%) and IgG alone was detected in 30 (51.72%) children. IgM/IgG antibody positivity to Toxoplasma, Rubella, CMV and HSV was 21(36.21%), 50(86.21%), 52(89.66%) and 8(13.79%) respectively. -
Orofacial Manifestations of COVID-19: a Brief Review of the Published Literature
CRITICAL REVIEW Oral Pathology Orofacial manifestations of COVID-19: a brief review of the published literature Esam HALBOUB(a) Abstract: Coronavirus disease 2019 (COVID-19) has spread Sadeq Ali AL-MAWERI(b) exponentially across the world. The typical manifestations of Rawan Hejji ALANAZI(c) COVID-19 include fever, dry cough, headache and fatigue. However, Nashwan Mohammed QAID(d) atypical presentations of COVID-19 are being increasingly reported. Saleem ABDULRAB(e) Recently, a number of studies have recognized various mucocutaneous manifestations associated with COVID-19. This study sought to (a) Jazan University, College of Dentistry, summarize the available literature and provide an overview of the Department of Maxillofacial Surgery and potential orofacial manifestations of COVID-19. An online literature Diagnostic Sciences, Jazan, Saudi Arabia. search in the PubMed and Scopus databases was conducted to retrieve (b) AlFarabi College of Dentistry and Nursing, the relevant studies published up to July 2020. Original studies Department of Oral Medicine and published in English that reported orofacial manifestations in patients Diagnostic Sciences, Riyadh, Saudi Arabia. with laboratory-confirmed COVID-19 were included; this yielded 16 (c) AlFarabi College of Dentistry and Nursing, articles involving 25 COVID-19-positive patients. The results showed a Department of Oral Medicine and Diagnostic Sciences, Riyadh, Saudi Arabia. marked heterogeneity in COVID-19-associated orofacial manifestations. The most common orofacial manifestations were ulcerative lesions, (d) AlFarabi College of Dentistry and Nursing, Department of Restorative Dental Sciences, vesiculobullous/macular lesions, and acute sialadentitis of the parotid Riyadh, Saudi Arabia. gland (parotitis). In four cases, oral manifestations were the first signs of (e) Primary Health Care Corporation, Madinat COVID-19. -
Oral Manifestations of Systemic Disease Their Clinical Practice
ARTICLE Oral manifestations of systemic disease ©corbac40/iStock/Getty Plus Images S. R. Porter,1 V. Mercadente2 and S. Fedele3 provide a succinct review of oral mucosal and salivary gland disorders that may arise as a consequence of systemic disease. While the majority of disorders of the mouth are centred upon the focus of therapy; and/or 3) the dominant cause of a lessening of the direct action of plaque, the oral tissues can be subject to change affected person’s quality of life. The oral features that an oral healthcare or damage as a consequence of disease that predominantly affects provider may witness will often be dependent upon the nature of other body systems. Such oral manifestations of systemic disease their clinical practice. For example, specialists of paediatric dentistry can be highly variable in both frequency and presentation. As and orthodontics are likely to encounter the oral features of patients lifespan increases and medical care becomes ever more complex with congenital disease while those specialties allied to disease of and effective it is likely that the numbers of individuals with adulthood may see manifestations of infectious, immunologically- oral manifestations of systemic disease will continue to rise. mediated or malignant disease. The present article aims to provide This article provides a succinct review of oral manifestations a succinct review of the oral manifestations of systemic disease of of systemic disease. It focuses upon oral mucosal and salivary patients likely to attend oral medicine services. The review will focus gland disorders that may arise as a consequence of systemic upon disorders affecting the oral mucosa and salivary glands – as disease. -
Viability of B. Typhosus in Stored Shell Oysters
PUBLIC HEALTH REPORTS VOL. 40 APRIL 24, 1925 No. 17 VIABILITY OF B. TYPHOSUS IN STORED SHELL OYSTERS By CONRAD KINYOuN, Assistant Bacteriologist, hlygienic Laboratory, United Stztes Ptiblic Ilealti Serviee The object of this work was to determine whether oysters con- taminated with B. typhosuis and then stored unider uisual market conditions woul(l remain potentially infectious over a length of time sufficient to allow them to reach the consumer. Conflicting opinions are now current as to the length of time the causative agent of typhoid fever can remain viable in the oyster, and even as to whether the oyster can harbor the organisms at all. Obviouisly an oyster which harbors typhoidl organismns for as short a time as 24 hours becomes a potential infecting, agent for thlat time. Practi- cally it is of interest to know whether the time elapsing between the remov-al of the oyster from the bed and( actual consumption after passing through customary commercial channels is sufficient for oysters to rid themselves of possible infection. As early as 1603, oysters were incriminate(d in intestinal disor(lers, when suspicion was directed toward them by an illness of Henry IV of France (7). It was not uIntil the close of the nineteenth century, however, that oysters and shellfislh as agents of (lisease transmission receive(d particular attention. In October, 1894, Conn focused attention on the oyster by his investigation of the now famous Wesleyan outbreak, an(d thoughl only thlree outbreaks of typhoid fever were definitely traced to the oyster before 19,25, these stimulated wide interest and consequent study, with atten(lant epidemiological and bacteriological investigations. -
Clinical Impact of Primary Infection with Roseoloviruses
Available online at www.sciencedirect.com ScienceDirect Clinical impact of primary infection with roseoloviruses 1 2 1 Brenda L Tesini , Leon G Epstein and Mary T Caserta The roseoloviruses, human herpesvirus-6A -6B and -7 (HHV- infection in different cell types, have the ability to reac- 6A, HHV-6B and HHV-7) cause acute infection, establish tivate, and may be intermittently shed in bodily fluids [3]. latency, and in the case of HHV-6A and HHV-6B, whole virus Unlike other human herpesviruses, HHV-6A and HHV- can integrate into the host chromosome. Primary infection with 6B are also found integrated into the host genome HHV-6B occurs in nearly all children and was first linked to the (ciHHV-6). Integration has been documented in 0.2– clinical syndrome roseola infantum. However, roseolovirus 1% of the general population and along with latency infection results in a spectrum of clinical disease, ranging from has confounded the ability to correlate the presence of asymptomatic infection to acute febrile illnesses with severe viral nucleic acid with active disease [4]. neurologic complications and accounts for a significant portion of healthcare utilization by young children. Recent advances The syndrome known as roseola infantum was reported as have underscored the association of HHV-6B and HHV-7 early as 1809 by Robert Willan in his textbook ‘On primary infection with febrile status epilepticus as well as the cutaneous diseases’ [5]. This clinical entity is also com- role of reactivation of latent infection in encephalitis following monly referred to as exanthem subitum and early pub- cord blood stem cell transplantation. -
Measles: Chapter 7.1 Chapter 7: Measles Paul A
VPD Surveillance Manual 7 Measles: Chapter 7.1 Chapter 7: Measles Paul A. Gastanaduy, MD, MPH; Susan B. Redd; Nakia S. Clemmons, MPH; Adria D. Lee, MSPH; Carole J. Hickman, PhD; Paul A. Rota, PhD; Manisha Patel, MD, MS I. Disease Description Measles is an acute viral illness caused by a virus in the family paramyxovirus, genus Morbillivirus. Measles is characterized by a prodrome of fever (as high as 105°F) and malaise, cough, coryza, and conjunctivitis, followed by a maculopapular rash.1 The rash spreads from head to trunk to lower extremities. Measles is usually a mild or moderately severe illness. However, measles can result in complications such as pneumonia, encephalitis, and death. Approximately one case of encephalitis2 and two to three deaths may occur for every 1,000 reported measles cases.3 One rare long-term sequelae of measles virus infection is subacute sclerosing panencephalitis (SSPE), a fatal disease of the central nervous system that generally develops 7–10 years after infection. Among persons who contracted measles during the resurgence in the United States (U.S.) in 1989–1991, the risk of SSPE was estimated to be 7–11 cases/100,000 cases of measles.4 The risk of developing SSPE may be higher when measles occurs prior to the second year of life.4 The average incubation period for measles is 11–12 days,5 and the average interval between exposure and rash onset is 14 days, with a range of 7–21 days.1, 6 Persons with measles are usually considered infectious from four days before until four days after onset of rash with the rash onset being considered as day zero. -
Measles Diagnostic Tool
Measles Prodrome and Clinical evolution E Fever (mild to moderate) E Cough E Coryza E Conjunctivitis E Fever spikes as high as 105ºF Koplik’s spots Koplik’s Spots E E Viral enanthem of measles Rash E Erythematous, maculopapular rash which begins on typically starting 1-2 days before the face (often at hairline and behind ears) then spreads to neck/ the rash. Appearance is similar to “grains of salt on a wet background” upper trunk and then to lower trunk and extremities. Evolution and may become less visible as the of rash 1-3 days. Palms and soles rarely involved. maculopapular rash develops. Rash INCUBATION PERIOD Fever, STARTS on face (hairline & cough/coryza/conjunctivitis behind ears), spreads to trunk, Average 8-12 days from exposure to onset (sensitivity to light) and then to thighs/ feet of prodrome symptoms 0 (average interval between exposure to onset rash 14 day [range 7-21 days]) -4 -3 -2 -1 1234 NOT INFECTIOUS higher fever (103°-104°) during this period rash fades in same sequence it appears INFECTIOUS 4 days before rash and 4 days after rash Not Measles Rubella Varicella cervical lymphadenopathy. Highly variable but (Aka German Measles) (Aka Chickenpox) Rash E often maculopapular with Clinical manifestations E Clinical manifestations E Generally mild illness with low- Mild prodrome of fever and malaise multiforme-like lesions and grade fever, malaise, and lymph- may occur one to two days before may resemble scarlet fever. adenopathy (commonly post- rash. Possible low-grade fever. Rash often associated with painful edema hands and feet. auricular and sub-occipital).